CognitiveInvestigational

Pinealon

Subcutaneous injection, Oral

Overview

Pinealon is a synthetic tripeptide (Glu-Asp-Arg) developed as part of the Khavinson peptide bioregulator series, designed to mimic endogenous short peptides that regulate gene expression in neural tissues. It is hypothesized to interact with chromatin and influence transcription of genes involved in neuronal survival and plasticity.

Mechanism of Action

Pinealon has been studied primarily in the context of age-related cognitive decline and neurodegenerative models..

Research Summary & Key Findings

Preclinical studies in rodent models of aging and neurodegeneration have reported improvements in memory, motor coordination, and markers of neuronal health, with data appearing in Russian pharmacology journals. Human clinical evidence remains sparse, with small observational studies suggesting subjective cognitive benefit in elderly populations. Peer-reviewed replication and placebo-controlled trials in international journals are lacking.

Clinical Status

Investigational

Pinealon is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.

Administration Routes

Subcutaneous injectionOral

Related Peptides in Cognitive

Find a Provider

Find a verified provider who offers Pinealon therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Pinealon.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.